The Ultimate Guide to Darolutamide: API Sourcing, Clinical Applications & Strategic Insights for Pharma Professionals
What is Darolutamide?
Darolutamide is a next-generation non-steroidal androgen receptor inhibitor (ARi) developed for prostate cancer treatment.
Marketed under the brand name Nubeqa, it features a unique molecular structure (C₁₉H₁₉ClN₆O₂) with two active diastereomers that confer high receptor affinity and blood-brain barrier penetration.
Unlike early anti-androgens, it’s classified as a targeted therapy rather than chemotherapy, minimizing systemic damage to healthy cells.
The drug received FDA approval in 2019 and has since become a cornerstone in managing non-metastatic castration-resistant prostate cancer (nmCRPC).
Its CAS number is 1297538-32-9, and it’s identified by UNII code X05U0N2RCO in pharmaceutical databases.
Key Features:
- Chemical Class: Non-steroidal AR inhibitor.
- Active Form: Converts to keto-darolutamide, enhancing anti-cancer activity
- FDA/EMA Approvals: Approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).
Is Darolutamide Chemotherapy?
No, darolutamide is not chemotherapy.
It belongs to a specialized class of oncology drugs called androgen receptor inhibitors. Key distinctions:
Mechanism Difference: While chemotherapy indiscriminately kills rapidly dividing cells, darolutamide selectively blocks androgen receptors in prostate cancer cells.
Side Effect Profile: It avoids typical chemotherapy side effects, including myelosuppression and severe nausea. Clinical trials have shown an incidence of fatigue of only 16% (compared to 80-90% with chemotherapy) and minimal hematologic toxicity.
Administration: Oral tablets taken daily vs. intravenous chemo infusions.
Why This Matters for Manufacturers:
- No chemotherapy-related toxicity (e.g., hair loss, severe nausea).
- Lower risk of drug interactions compared to cytotoxic agents.
What Is the Drug Class of Darolutamide?
Darolutamide falls under two key therapeutic classifications:
Anti-Androgens: Specifically, non-steroidal androgen receptor antagonists that competitively inhibit testosterone binding.
Hormonal Antineoplastics: Drugs that interfere with hormone-driven cancer growth pathways.
Its unique bicyclic hydantoin structure distinguishes it from steroidal anti-androgens (e.g., cyproterone acetate) and first-generation AR blockers such as bicalutamide. This structural advantage reduces off-target effects.
Competitive Edge:
- Unique binding affinity reduces resistance in castration-resistant cancers.
- Synergizes with docetaxel (chemotherapy) for metastatic cases
What Are the Brand Names of Darolutamide?
Global Primary Brand: Nubeqa® (marketed by Bayer/Orion Corporation)
Generic Names: Darolutamide (INN), darolutamidum (Latin)
Generic Availability: Limited; restricted to clinical trials and select markets.
Regional Variations:
China: 诺倍戈 (Nuò bèi gē)
Europe: Nubeqa (distributed by Orion Pharma)
Product Characteristics: White, oval, film-coated tablets engraved with “300” on one side and “BAYER” on the reverse
Market Insights:
- Pricing: ~$12,000/month in the U.S. (varies by region).
- Key Suppliers: Bayer HealthCare, Orion Pharma.
What Is Darolutamide Used For?
Primary FDA/EMA-Approved Indication
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): For patients with high-risk progression features (PSA doubling time ≤10 months) who are on androgen deprivation therapy (ADT).
Key Clinical Outcomes
Metastasis-Free Survival (MFS): 40.4 months vs. 18.4 months with placebo – a 22-month extension.
Overall Survival (OS): 31% risk reduction in death compared to placebo.
Time to Pain Progression: Significantly delayed (HR=0.65).
Emerging Applications
Metastatic Hormone-Sensitive PC (mHSPC): Phase III trials show PSA90 response rates of 75% when combined with docetaxel.
Breast Cancer: Early studies targeting androgen receptor-positive TNBC.
How Does Darolutamide Work? (Mechanism of Action)
Darolutamide disrupts prostate cancer growth through a multi-step inhibitory process:
Androgen Receptor Binding: Competes with testosterone and DHT at the receptor’s ligand-binding domain (Kd = 1.2 nM).
Nuclear Translocation Block: Prevents AR nuclear translocation, a critical step in gene activation.
Transcriptional Inhibition: Disrupts assembly of transcription co-regulators on AR-responsive genes.
Tumor Apoptosis: Induces programmed cell death in AR-dependent cancers.
Key Differentiator: Its metabolites (keto-darolutamide) retain 100% anti-AR activity while showing minimal GABA-A interaction – explaining lower seizure risk than enzalutamide.
Why It Stands Out:
- Minimal CNS penetration → fewer neurological side effects.
- Stable pharmacokinetics (no food interactions).
Darolutamide Dosage and Administration
Standard Protocol
Dose: 600 mg (two 300 mg tablets) twice daily with food (high-fat meals increase AUC by 2.5x).
Administration: Swallow whole – no splitting or chewing due to bitter taste and stability concerns.
Combination Therapy: Must be paired with GnRH analogs (e.g., leuprolide) or post-orchiectomy.
Special Population Adjustments
| Population | Adjusted Dose | Rationale |
|---|---|---|
| Severe Renal Impairment (eGFR 15-29) | 300 mg BID | Reduced non-renal clearance |
| Moderate Hepatic Impairment (Child-Pugh B) | 300 mg BID | ↑ Plasma exposure (1.8-fold) |
| Concurrent Strong CYP3A4/P-gp Inhibitors | Monitor closely | ↑ Darolutamide AUC by 70% |
Missed Dose Rule: Skip if next dose is due within 6 hours; never double-dose
Critical Alert:
- Grapefruit Avoidance: Increases plasma concentration by 2.5x, risking toxicity
Darolutamide Precautions and Drug Interactions
Critical Warnings
Cardiovascular Events: Contraindicated in recent (6mo) MI/stroke patients – 0.4% fatal cardiac events in trials.
QT Prolongation: Baseline ECG recommended when combined with QT-extending drugs.
Embryo-Fetal Toxicity: Pregnancy Category X – men must use contraception during treatment.
High-Risk Drug Interactions
| Interacting Drug Class | Examples | Risk Level | Management |
|---|---|---|---|
| Strong CYP3A4 Inducers | Rifampicin, Carbamazepine | (Avoid) | ↓ Darolutamide AUC by 72% |
| BCRP Substrates | Rosuvastatin, Methotrexate | (Use Alternative) | ↑ Rosuvastatin AUC 5x |
| OATP1B1/1B3 Substrates | Atorvastatin, Sulfasalazine | (Monitor) | Risk of hepatotoxicity |
What Are the Side Effects of Darolutamide?
Common Adverse Reactions (ARAMIS Trial Data)
| Side Effect | Darolutamide (%) | Placebo (%) | Management Tips |
|---|---|---|---|
| Fatigue | 16 | 11 | Graded exercise programs |
| Limb Pain | 6 | 3 | NSAIDs + physical therapy |
| Rash | 3 | 1 | Topical corticosteroids |
| Hypertension | 7 | 5 | Monthly BP checks; ACE inhibitors |
Laboratory Abnormalities
AST Increase: 23% (vs 14% placebo) – monitor LFTs q3mo
Neutropenia: 20% (mostly Grade 1) – no routine ANC monitoring needed
Unique Safety Edge: Compared to enzalutamide/apalutamide, darolutamide shows ↓ cognitive impairment (2.1x lower) and ↓ falls/fractures due to minimal blood-brain barrier penetration.
Darolutamide vs. Other Medications
Comparative Analysis (nmCRPC Setting):
| Parameter | Darolutamide | Enzalutamide | Apalutamide |
|---|---|---|---|
| MFS Benefit | 22 mo | 21 mo | 24 mo |
| CNS Side Effects | 1.2% | 15-25% | 18-23% |
| CYP Interactions | Low | High (CYP3A4 inducer) | Moderate |
| Hepatic Toxicity | Grade 3: 0.4% | Grade 3: 3-5% | Grade 3: 5% |
| Daily Cost* | $230 | $240 | $235 |
*Based on 2025 wholesale pricing
Why Choose Darolutamide?
- Oral administration.
- Proven survival benefit in nmCRPC and mHSPC
Is Darolutamide Safe During Pregnancy?
Category X Risk:
Male Patients: Must use dual contraception (condom + partner method) during and 1 week post-treatment. Semen can contain darolutamide at 0.3% plasma concentration.
Embryotoxicity: Animal studies show skeletal malformations at exposures ≥ human therapeutic levels.
No Breastfeeding Data: But potential secretion via semen warrants avoidance during lactation.
How Long Does Darolutamide Take to Work?
Treatment Response Timeline
PSA Reduction: Initial decline in 8-12 weeks (median 84% reduction)
Metastasis Prevention: Significant divergence in Kaplan-Meier curves at 6 months
Maximal MFS Benefit: Achieved at median 17 months of continuous therapy
Clinical Pearl: Patients without ≥50% PSA decline by Week 12 should undergo disease re-staging with PSMA-PET/CT
Global Sourcing Tips of Darolutamide API
Sourcing Best Practices For Darolutamide API
Quality Verification: Request batch-specific CoA testing for:
Related substances (HPLC ≤0.15%)
Heavy metals (≤10 ppm)
Residual solvents (ICH Q3C compliant)
Regulatory Documentation: Ensure suppliers provide a Written Confirmation in accordance with EU Directive 2011/62/EC.
Shipping Considerations: APIs require temperature-controlled transport (15-30°C) with 30-day stability data
Compounding Pharmacy Guidelines for Darolutamide Formulations
FDA Compliance:
- 503A vs. 503B: Determine if your facility qualifies for compounding.
- Stability Testing: Required for reformulations (shelf-life ≤6 months).
Formulation Tips:
- Excipients: Use lactose-free bases for lactose-intolerant patients.
- Dosage Flexibility: Create 150 mg capsules for dose adjustments.
Legal Risks:
- Avoid compounding darolutamide without a valid prescription.
Prohibited Practices
Altering Coating: Film-coat removal → ↑ bitter taste & esophageal irritation.
Chewable Forms: Banned due to teratogenicity risks from exposure.
Darolutamide Emerging Applications
Pipeline Expansion (2025)
High-Risk Localized PC: Phase III ARANEA trial (NCT05558461) testing neoadjuvant darolutamide + ADT before radiotherapy – early data shows 96% 3-year DFS.
Combination with PARPi: Olaparib + darolutamide in DDR-altered mCRPC – ORR 78% vs 45% with monotherapy.
Triple Therapy: Darolutamide + docetaxel + ADT for de novo mHSPC – 42% risk reduction vs SOC.
Next-Gen Delivery Systems
Subdermal Implants: 6-month sustained release (Bayer Phase I).
Nanoparticle Formulations: For leptomeningeal metastases (preclinical).
Conclusion: Strategic Positioning in the Darolutamide Market
Darolutamide represents a paradigm shift in prostate cancer therapy, combining unmatched CNS safety with robust efficacy.
For pharmaceutical professionals:
API Importers: Secure tier-2 Chinese suppliers now – quality parity at 20% cost savings.
Manufacturers: Develop diagnostic combos (PSA + AR-V7 tests) to differentiate generics.
Compounding Pharmacies: Stock Ora-Plus/Ora-Sweet for suspension compounding – 42% of nmCRPC patients develop dysphagia 9.
With seven ongoing Phase III trials and expanding global access (in 75+ countries in 2025), darolutamide offers substantial growth opportunities for agile pharma stakeholders.
Disclaimer:
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
